Considerations with the use of biological therapy in the treatment of rheumatoid arthritis

Expert Opinion on Drug Safety
Roy FleischmannRichard Stern

Abstract

The treatment of rheumatoid arthritis (RA) has changed dramatically over the past 15 years with the realisation that earlier, aggressive therapy limits progression. There is evidence that biological response modifiers (BRMs), which target specific cytokines such as TNF-alpha and IL-1, are more effective than traditional disease-modifying antirheumatic drugs (DMARDs), especially in combination with methotrexate. Four therapies are approved for use in RA; three target TNF-alpha (etanercept [Enbrel, Amgen Inc.], infliximab [Remicade, Centocor Inc.], and adalimumab [Humira, Abbott]), and one targets IL-1 (anakinra [Kineret, Amgen Inc.]). It is clear from both the clinical trials and postmarketing reports that all four agents have a different safety profile compared with traditional DMARDs. There are several areas of concern with the use of the BRMs, which include serious and opportunistic infections, malignancy/lymphoma, congestive heart failure, demyelination, injection/infusion reactions, development of autoantibodies and lupus-like disease. It is important to be fully aware of the safety profile and differences between BRMs in order to use them appropriately.

References

Jan 1, 1978·Journal of Chronic Diseases·H A IsomäkiU Joutsenlahti
Mar 1, 1991·The Journal of Clinical Investigation·K SelmajC F Brosnan
Jan 1, 1990·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·S T MalikF R Balkwill
Aug 1, 1989·The Journal of Experimental Medicine·F M HofmanJ E Merrill
Feb 17, 1993·Journal of the National Cancer Institute·G GridleyJ F Fraumeni
Jul 1, 1994·Clinical and Diagnostic Laboratory Immunology·K Kuus-ReichelN E Kay
Sep 1, 1996·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·L MellemkjaerJ H Olsen
Dec 31, 1998·Arthritis and Rheumatism·B BresnihanP Musikic
Mar 13, 1999·Annals of Internal Medicine·L W MorelandM E Weinblatt
Jul 8, 1999·Nature Medicine·N L Michael, J P Moore
Jan 6, 2000·Seminars in Arthritis and Rheumatism·P BeauparlantB Haraoui
Nov 30, 2000·The New England Journal of Medicine·J M BathonB K Finck
Nov 30, 2000·The New England Journal of Medicine·P E LipskyUNKNOWN Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group
Mar 13, 2001·Annual Review of Immunology·J L Flynn, J Chan
Oct 13, 2001·The New England Journal of Medicine·J KeaneM M Braun
Apr 19, 2002·The Journal of Pharmacology and Experimental Therapeutics·Bernie ScallonCarrie Wagner
May 1, 2002·Current Opinion in Rheumatology·Lisa G Criscione, E William St Clair
Aug 15, 2002·Annals of the Rheumatic Diseases·R A Asherson, L Pascoe
Oct 2, 2002·Annals of Internal Medicine·Yousaf Ali, Samir Shah
Nov 7, 2002·International Journal of Cardiology·Stefan D Anker, Andrew J S Coats
Feb 14, 2003·The New England Journal of Medicine·Filip BaertPaul Rutgeerts
Feb 28, 2003·Clinical Rheumatology·M DebandtO Meyer
Mar 5, 2003·The Lancet Infectious Diseases·Michael A GardamDonald C Vinh

❮ Previous
Next ❯

Citations

Sep 24, 2010·Zeitschrift für Rheumatologie·I H TarnerC Hamm
Dec 23, 2006·Clinical Rheumatology·Taha Rashid, Alan Ebringer
Jan 9, 2007·Clinical Rheumatology·Taha Rashid, Alan Ebringer
Jan 18, 2007·Clinical Rheumatology·Salvatore CorraoGiuseppe Licata
Feb 14, 2008·Internal and Emergency Medicine·Salvatore CorraoGiuseppe Licata
Apr 18, 2007·Current Allergy and Asthma Reports·Jiyoun Kim, Daniel G Remick
Sep 10, 2005·Annals of the Rheumatic Diseases·R FleischmannP Peloso
Oct 14, 2006·Annals of the Rheumatic Diseases·D E FurstM H Weisman
Nov 21, 2007·Annals of the Rheumatic Diseases·D E FurstM E Weinblatt
Apr 28, 2005·BMC Clinical Pharmacology·Simon K Mencher, Long G Wang
Nov 25, 2005·Australia and New Zealand Health Policy·Christine Y LuRichard O Day
May 21, 2008·Australia and New Zealand Health Policy·Christine Y LuRic Day
Aug 26, 2010·Arthritis Research & Therapy·Matthias Geyer, Ulf Müller-Ladner
Jun 27, 2014·Journal of Obstetrics and Gynaecology of India·Ashok Kumar
Sep 1, 2005·Expert Review of Clinical Immunology·Mathias Grunke, Joachim Robert Kalden
Dec 24, 2005·Expert Opinion on Pharmacotherapy·Roy FleischmannRichard L Stern
Jan 29, 2011·Expert Opinion on Biological Therapy·Matthew B Carroll
Jun 7, 2005·Expert Opinion on Pharmacotherapy·J Peter Kaltwasser, Frank Behrens
Sep 1, 2009·Autoimmunity Reviews·Siba P RaychaudhuriM Eric Gershwin
Jun 19, 2009·Journal of the American Academy of Dermatology·Bruce StroberMelodie Young
Jun 14, 2008·Journal of the Neurological Sciences·Hirotoshi KikuchiShunsei Hirohata
Jan 2, 2008·Seminars in Arthritis and Rheumatism·John C Davis, Philip J Mease
Jul 3, 2008·American Journal of Reproductive Immunology : AJRI·Gerard Chaouat
Oct 4, 2005·Journal of the American Academy of Dermatology·Warren R Heymann
May 21, 2016·Inflammatory Bowel Diseases·Mathurin FumeryUNKNOWN EPIMAD group
May 20, 2005·Seminars in Cutaneous Medicine and Surgery·Jennifer Clay Cather, Alan Menter
Dec 17, 2005·Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases·Paul Emery
Mar 12, 2005·Human Reproduction·Raj RaiGeoffrey Trew
May 7, 2019·Expert Review of Clinical Pharmacology·Qian QiuMingxing Guo

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.